Hybrid Trial of a Digital Therapeutic for Smoking Cessation Among Persons Living With HIV

What this Trial Is About

This research aims to compare two different smartphone apps designed to help people living with HIV (PWH) quit smoking. Smoking rates are much higher among PWH compared to the general population, and smoking causes more life years lost in this group than HIV itself. The study focuses on evaluating digital therapeutics tailored for smoking cessation in PWH, addressing a critical need for effective and scalable interventions in this population. Participants will be randomly assigned to use either a digital therapeutic app tailored for people with HIV or an app designed for the general population. Both groups will also receive nicotine replacement therapy (patches and gums) to support quitting smoking. The apps provide smoking cessation education, skills training, and support over a 24-week period, with content delivered in modules across the study duration. During the approximately 6-month study, participants will complete five video call visits to meet with study staff, complete questionnaires, and participate in interviews. They may provide breath and saliva samples to measure carbon monoxide and nicotine levels. Researchers will assess smoking abstinence through biochemical verification and self-reported measures at multiple timepoints, as well as track app usage and quit attempts. Safety and adherence will be monitored throughout the study.

Quitting Matters Human Immunodeficiency Virus Hybrid Trial